Clinical trials
Liver Fibrosis clinical trials
Below are recruiting liver fibrosis clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06561529Recruiting
Stomach bypass stent for liver scarring in obese patients
This study tests a stomach bypass stent to treat liver scarring caused by fatty liver disease in people with obesity. If you have obesity and a confirmed liver condition called NASH with moderate scarring, this stent might help you achieve weight loss and improve your liver health.
Riga, RigaAges 18–65 - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT06098417Recruiting
Fatty liver markers before weight-loss surgery
This study looks at special markers in the blood to better understand and predict a fatty liver condition called NAFLD. It focuses on people who are very overweight and are already planning to have weight-loss surgery.
TriesteAges 18–65 - NCT06119997Recruiting
Liver fibrosis screening using simple blood tests in primary care
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
GrenobleAges 18–70 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT06814600Recruiting
Fatty liver study in inflammatory bowel disease patients
This study checks how often people with Crohn's or ulcerative colitis also have fatty liver disease. It uses a painless scan to measure liver stiffness and fat. If you have IBD, you may join to help researchers learn about the link between these conditions.
BrusselsAges 18 years+ - NCT03472157Recruiting
Bariatric surgery for severe NASH with advanced liver scarring
This study tests whether bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) improves severe nonalcoholic steatohepatitis (NASH) with advanced liver scarring in people who are obese. You may also need liver biopsies to confirm your liver disease before and after treatment.
LilleAges 18–65 - NCT04681573Recruiting
Tests two non-invasive ways to check liver scarring
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
AngersAges 18–80 - NCT05526144RecruitingPhase 2
Thyroid hormone treatment for fatty liver in Veterans
This trial tests whether thyroid hormone can improve nonalcoholic steatohepatitis (fatty liver with inflammation) in Veterans. You may be asked to have a medically needed liver biopsy, and the study also focuses on safety in people with related conditions like diabetes and heart risks.
Columbia, MissouriAges 18–75 - NCT05692024RecruitingPhase 1/Phase 2
Coffee and gut bacteria study after colon or rectal cancer
This early-phase study tests whether a coffee-related approach can change gut bacteria and blood “metabolites” after treatment for stage I–III colon or rectal cancer. The goal is to learn if these changes could help improve health after standard cancer treatment.
Boston, MassachusettsAges 18 years+ - NCT06564740Recruiting
Stem cell therapy for infants with biliary atresia and cirrhosis
This study is testing whether stem cells can help infants with liver cirrhosis from biliary atresia (a blocked bile duct condition) who have already had Kasai surgery. It aims to see if stem cell therapy can improve liver function and reduce complications.
Istanbul, IstanbulAges 2 months–18 years - NCT01757730Recruiting
MRI test to measure soft tissue stiffness
This trial uses a special type of MRI to estimate how stiff certain soft tissues are in the body. You may benefit by helping doctors better measure tissue stiffness, which can relate to different health problems.
Columbus, OhioAges 18 years+ - NCT07400367Recruiting
Probiotics and lifestyle changes for fatty liver disease
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
New Taipei CityAges 18–80 - NCT07471542Recruiting
Copper supplements for cirrhosis patients
This trial tests whether taking copper supplements can help people with cirrhosis (scarring of the liver) who have low copper levels or symptoms related to copper deficiency. It aims to see if this can improve their health.
Seattle, WashingtonAges 18 years+ - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT03025074Recruiting
Blood sample bank for liver disease research
This study collects blood samples to build a “biobank” (a stored library of samples) for researchers studying liver diseases like hepatitis, fatty liver disease, and liver cancer. It may help future testing and treatments by allowing scientists to study patterns in people with and without liver conditions.
Buffalo, New YorkAges 7 years+ - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Birmingham, AlabamaAges 18–75 - NCT07312136Enrolling by invitation
Liver health follow-up in type 2 diabetes
This study follows up on people who already joined the EPSONIP trial to check how their liver health (MASLD) has changed over time. It uses MRI to look at the liver and does not test any new medicine.
Linköping, Östergötland CountyAges 18 years+ - NCT05385237Recruiting
4D MRI scan to spot liver scarring
This study tests whether a special MRI scan (called 4D-MRI) can identify liver scarring or damage. It may help doctors measure liver fibrosis and inflammation without relying only on invasive tests.
Liestal, Basel-LandschaftAges 18 years+ - NCT07128108Recruiting
Testing a new ultrasound for liver fat and scarring
This study tests a new ultrasound technique called Visual Transient Elastography (ViTE) to measure fat and scarring in the liver. If you recently had a liver biopsy, this noninvasive test could help check your liver health without another needle procedure.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06755632Recruiting
Hepatic fibrosis or cirrhosis screening trial
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
BobignyAges 18 years+ - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT07440511Recruiting
Spleen stiffness test for advanced liver scarring
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
RomeAges 18 years+
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver fibrosis?
- Yes. Clin2 currently lists 79 recruiting liver fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.